In the Media | H3 Biomedicine

Scrip

Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the… Read More

Fierce Biotech

Chutes & Ladders

Eisai's cancer genomics drug discovery subsidiary, H3 Biomedicine, promoted Ping Zhu, Ph.D., to president and chief scientific officer, and Ross… Read More

NJBIZ

Eisai subsidiary appoints new leadership

H3 Biomedicine, a cancer genomics-based drug discovery subsidiary company of Woodcliff Lake pharmaceutical company Eisai, appointed a new executive leadership… Read More

Bio-IT World

H3’s Data Centric Approach to Cancer Genomics

Lihua Yu began her training as a biomedical engineer during her undergraduate studies, but for her Ph.D. training, she chose… Read More

Scrip

Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19

Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key… Read More

BioPharm Insight

H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO

H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More

Boston Business Journal

H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug

Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More

PharmaVOICE

H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100

In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More

Boston Business Journal

Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs

A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More

FasterCures

Fixes in Financing

High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More